| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
11,447,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
23,616 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.000001 - $0.008 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Anthera Pharmaceuticals is a biopharmaceutical company focused on advancing the development and commercialization of medicines that benefit patients with medical needs. Co. has two compounds in development, Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy intended for the treatment of patients with Exocrine Pancreatic Insufficiency, often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Thompson John Craig |
President & CEO |
• • – |
2017-09-20 |
4 |
B |
$1.32 |
$11,286 |
D/D |
8,550 |
19,848 |
0.01 |
- |
|
| Thompson John Craig |
President & CEO |
• • – |
2017-09-07 |
4/A |
B |
$1.43 |
$14,893 |
D/D |
10,400 |
11,298 |
2.81 |
- |
|
| Truex Paul F |
|
– • – |
2017-09-07 |
4 |
B |
$1.34 |
$6,700 |
I/I |
5,000 |
16,793 |
0.01 |
- |
|
| Thompson John Craig |
President & CEO |
• • – |
2017-09-07 |
4 |
OE |
$1.43 |
$14,893 |
D/D |
10,400 |
17,590 |
|
- |
|
| Thompson John Craig |
Chief Executive Officer |
• – – |
2017-01-11 |
5 |
A |
$0.55 |
$3,955 |
D/D |
7,190 |
7,190 |
|
- |
|
| Olson Charles V |
CHIEF TECHNOLOGY OFFICER |
• – – |
2017-01-11 |
5 |
A |
$0.55 |
$4,272 |
D/D |
7,767 |
17,519 |
|
- |
|
| Truex Paul F |
Chief Executive Officer |
• – – |
2016-09-20 |
4 |
GA |
$0.00 |
$0 |
I/I |
5,008 |
94,345 |
|
- |
|
| Truex Paul F |
Chief Executive Officer |
• – – |
2016-09-20 |
4 |
GD |
$0.00 |
$0 |
D/D |
5,008 |
0 |
|
- |
|
| Truex Paul F |
Chief Executive Officer |
• – – |
2016-09-20 |
4 |
OE |
$2.08 |
$10,417 |
D/D |
5,008 |
5,008 |
|
- |
|
| Olson Charles V |
CHIEF TECHNOLOGY OFFICER |
• – – |
2016-06-30 |
5 |
A |
$2.63 |
$4,705 |
D/D |
1,789 |
9,752 |
|
- |
|
| Pennington James |
Interim Chief Medical Officer |
• – – |
2016-04-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
17,688 |
|
- |
|
| Olson Charles V |
CHIEF TECHNOLOGY OFFICER |
• – – |
2016-01-05 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
7,963 |
|
- |
|
| Mueller Brian |
|
– • – |
2015-12-23 |
4 |
OE |
$2.89 |
$28,900 |
D/D |
10,000 |
10,000 |
|
- |
|
| Hislop Colin |
Chief Medical Officer |
• – – |
2015-11-13 |
4 |
AS |
$5.31 |
$66,341 |
D/D |
(12,500) |
19,147 |
|
- |
|
| Hislop Colin |
Chief Medical Officer |
• – – |
2015-11-13 |
4 |
OE |
$1.61 |
$20,125 |
D/D |
12,500 |
31,647 |
|
- |
|
| Hislop Colin |
Chief Medical Officer |
• – – |
2015-11-11 |
4 |
S |
$5.38 |
$26,900 |
D/D |
(5,000) |
19,147 |
|
- |
|
| Odink Debra |
Chief Technology Officer |
• – – |
2015-10-12 |
4 |
AS |
$6.15 |
$7,411 |
D/D |
(1,205) |
7,896 |
|
- |
|
| Dickinson Klara |
SVP & Chief Regulatory Office |
• – – |
2015-06-30 |
5 |
A |
$1.49 |
$18,625 |
D/D |
12,500 |
12,500 |
|
- |
|
| Liu May |
SVP, Finance & Administration |
• – – |
2015-06-30 |
5 |
A |
$1.49 |
$18,625 |
D/D |
12,500 |
32,302 |
|
- |
|
| Truex Paul F |
Chief Executive Officer |
• – – |
2015-06-30 |
5 |
GD |
$0.00 |
$0 |
I/I |
12,500 |
89,337 |
|
- |
|
| Truex Paul F |
Chief Executive Officer |
• – – |
2015-06-30 |
5 |
A |
$0.00 |
$0 |
I/I |
12,500 |
101,837 |
|
- |
|
| Truex Paul F |
Chief Executive Officer |
• – – |
2015-06-30 |
5 |
D |
$0.00 |
$0 |
D/D |
(12,500) |
0 |
|
- |
|
| Truex Paul F |
Chief Executive Officer |
• – – |
2015-06-30 |
5 |
A |
$1.49 |
$18,625 |
D/D |
12,500 |
12,500 |
|
- |
|
| Zenyaku Kogyo Co., Ltd. |
10% Owner |
– – • |
2015-01-27 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,795,895 |
|
- |
|
| Truex Paul F |
President and CEO |
• – – |
2014-12-31 |
4 |
GA |
$0.00 |
$0 |
I/I |
12,500 |
89,337 |
|
- |
|
32 Records found
|
|
Page 1 of 2 |
|
|
